All lobbying filings

TIBER CREEK GROUP

TIBER CREEK GROUP filed a Q3 report for AMGEN INC on October 19, 2026, reporting $60,000 in lobbying income.

Lobbying for AMGEN INC

All filings by TIBER CREEK GROUP · Everything AMGEN INC has reported

Filing · LD-2 quarterly report Q3 report

Reporting period

3rd Quarter 2026

July 1 - Sep 30 · Posted Oct 19, 2026

Income

$60,000

What the client paid this registrant for the period.

Client based in

District of Columbia

Official filing document

Government bodies contacted 2

The chambers, agencies and offices the filer named. It does not say who inside them was contacted, or when. Each name opens every filing that named the same body.

Lobbying activity 2

Medicare/Medicaid

Issues related to Medicare and Medicaid drug pricing; Issues related to biosimilar access and affordability; Issues related to H.R. 10628/S.5571 - Biosimilars Access and Affordability Act.

Health Issues

Issues related to the 340B Program - Public Health Service Act (PL 78-410); Issues related to H.R. 5526/S. 1954 - Biosimilar Red Tape Elimination Act.

Bills named in this filing 4

H.R. 10628
Biosimilars Access and Affordability Act
S. 5571
Biosimilars Access and Affordability Act
H.R. 5526
Biosimilar Red Tape Elimination Act
S. 1954
Biosimilar Red Tape Elimination Act

Source: federal Lobbying Disclosure Act filing, reproduced as filed. Bills are parsed from the activity descriptions.